Clinical value of 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography for diagnosis, staging and assessing therapy response in lung cancer
Open Access
- 2 July 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Insights into Imaging
- Vol. 12 (1), 1-21
- https://doi.org/10.1186/s13244-021-01026-1
Abstract
Lung cancer has the highest mortality rate of any tumour type. The main driver of lung tumour growth and development is uncontrolled cellular proliferation. Poor patient outcomes are partly the result of the limited range of effective anti-cancer therapies available and partly due to the limited accuracy of biomarkers to report on cell proliferation rates in patients. Accordingly, accurate methods of diagnosing, staging and assessing response to therapy are crucial to improve patient outcomes. One effective way of assessing cell proliferation is to employ non-invasive evaluation using 3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT) positron emission tomography [18F]FLT-PET. [18F]FLT, unlike the most commonly used PET tracer [18F]fluorodeoxyglucose ([18F]FDG), can specifically report on cell proliferation and does not accumulate in inflammatory cells. Therefore, this radiotracer could exhibit higher specificity in diagnosis and staging, along with more accurate monitoring of therapy response at early stages in the treatment cycle. This review summarises and evaluates published studies on the clinical use of [18F]FLT to diagnose, stage and assess response to therapy in lung cancer.Keywords
Funding Information
- Saudi Arabia Cultural Bureau in London
This publication has 58 references indexed in Scilit:
- Sulfotransferase 1A1 (SULT1A1) gene expression is regulated by members of the NFI transcription factors in human breast cancer cellsBMC Clinical Pathology, 2014
- Pemetrexed Induced Thymidylate Synthase Inhibition in Non-Small Cell Lung Cancer Patients: A Pilot Study with 3′-Deoxy-3′-[18F]fluorothymidine Positron Emission TomographyPLOS ONE, 2013
- Prognostic Impact of [18F]Fluorothymidine and [18F]Fluoro-D-Glucose Baseline Uptakes in Patients with Lung Cancer Treated First-Line with ErlotinibPLOS ONE, 2013
- Thymidine Kinase 1 Upregulation Is an Early Event in Breast Tumor FormationJournal of Oncology, 2012
- Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximabBMC Medicine, 2012
- 3′-Deoxy-3′-18F-Fluorothymidine PET/CT to Guide Therapy with Epidermal Growth Factor Receptor Antagonists and Bcl-xL Inhibitors in Non–Small Cell Lung CancerJournal of Nuclear Medicine, 2012
- Quantitative Analysis of Response to Treatment with Erlotinib in Advanced Non–Small Cell Lung Cancer Using 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PETJournal of Nuclear Medicine, 2011
- Progression-Free Survival as a Primary Endpoint in Clinical Trials of Metastatic Colorectal CancerCurrent Oncology, 2011
- Different Modes of Transport for 3H-Thymidine, 3H-FLT, and 3H-FMAU in Proliferating and Nonproliferating Human Tumor CellsJournal of Nuclear Medicine, 2010
- Imaging Cellular Proliferation During Chemo-Radiotherapy: A Pilot Study of Serial 18F-FLT Positron Emission Tomography/Computed Tomography Imaging for Non–Small-Cell Lung CancerEndocrine, 2009